Andere Kunden interessierten sich auch für
![Real-World Evidence Generation and Evaluation of Therapeutics]( "Real-World Evidence Generation and Evaluation of Therapeutics")
Real-World Evidence Generation and Evaluation of Therapeutics60,99 €![Advancing the Discipline of Regulatory Science for Medical Product Development]( "Advancing the Discipline of Regulatory Science for Medical Product Development")
Advancing the Discipline of Regulatory Science for Medical Product Development45,99 €![Building Resilience Into the Nation's Medical Product Supply Chains]( "Building Resilience Into the Nation's Medical Product Supply Chains")
Building Resilience Into the Nation's Medical Product Supply Chains50,99 €![Impact of the Global Medical Supply Chain on Sns Operations and Communications]( "Impact of the Global Medical Supply Chain on Sns Operations and Communications")
Impact of the Global Medical Supply Chain on Sns Operations and Communications60,99 €![Examining the History, Consequences, and Effects of Race-Based Clinical Algorithms on Health Equity]( "Examining the History, Consequences, and Effects of Race-Based Clinical Algorithms on Health Equity")
Examining the History, Consequences, and Effects of Race-Based Clinical Algorithms on Health Equity21,99 €![Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Product Development]( "Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Product Development")
Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Product Development32,99 €![Evaluating the Impact of Implementing Evidence-Based Practice]( "Evaluating the Impact of Implementing Evidence-Based Practice")
Evaluating the Impact of Implementing Evidence-Based Practice61,99 €
Randomized controlled trials (RCTs) have traditionally served as the gold standard for generating evidence about medical interventions. However, RCTs have inherent limitations and may not reflect the use of medical products in the real world. Additionally, RCTs are expensive, time consuming, and cannot answer all questions about a product or intervention. Evidence generated from real-world use, such as real-world evidence (RWE) may provide valuable information, alongside RCTs, to inform medical product decision making. To explore the potential for using RWE in medical product decision making, the National Academies of Sciences, Engineering, and Medicine planned a three-part workshop series. The series was designed to examine the current system of evidence generation and its limitations, to identify when and why RWE may be an appropriate type of evidence on which to base decisions, to learn from successful initiatives that have incorporated RWE, and to describe barriers that prevent RWE from being used to its full potential. This publication summarizes the discussions from the entire workshop series.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.